Veppanu cleared for ESR1m, ER+/HER2- advanced breast cancer

What this means

Veppanu is an oral breast cancer drug that works by breaking down specific proteins that fuel tumor growth in certain advanced breast cancers. Today FDA approved Veppanu for patients with ER+/HER2- advanced breast cancer that has a specific mutation called ESR1m. This approval gives patients with this hard-to-treat mutation a new option that may help slow disease progression when other treatments stop working.